Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

This study has been withdrawn prior to enrollment.
(strategic decision)
Sponsor:
Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:
NCT00908414
First received: May 21, 2009
Last updated: October 27, 2016
Last verified: October 2016
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: October 2009
  Estimated Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)